Abstract
Stable amides of clozapine derived from fatty acids prominent in cerebral tissue might enhance the central activity of clozapine and reduce its exposure to peripheral tissues. Such derivatives might enhance the safety of this unique drug, which is the only agent with securely established superior antipsychotic effectiveness, but with a risk of potentially lethal systemic toxicity. Amide derivatives of clozapine were prepared from structurally varied fatty acid chlorides and evaluated for ability to inhibit behavioral arousal in rat induced by dopamine agonist apomorphine and to induce catalepsy. Their duration-of-action and potency were compared to free clozapine, and concentrations of clozapine were assayed in brain and blood. Selected agents were also evaluated for affinity at dopamine receptors and other potential drug-target sites. Clozapine-N-amides of linoleic, myristic, oleic, and palmitic acids had moderate initial central depressant activity but by 6 h, failed to inhibit arousal induced by apomorphine. However, the docosahexaenoic acid (DHA) derivative was orally bioavailable, 10-times more potent (ED50 5.0 μmol/kg) than clozapine itself, and very long-acting (≥ 24 h) against apomorphine, and did not induce catalepsy. DHA itself was inactive behaviorally. Clozapine showed expected dopamine receptor affinities, but DHA-clozapine was inactive at these and other potential target sites. After systemic administration of DHA-clozapine, serum levels of free clozapine were very low, and brain concentrations somewhat lower than after administering clozapine. DHA-clozapine is a long-acting central depressant with powerful and prolonged antidopaminergic activity after oral administration or injection without inducing catalepsy, and it markedly reduced peripheral exposure to free clozapine. It lacked the receptor-affinities shown by clozapine, suggesting that DHA-clozapine may be a precursor of free, pharmacologically active clozapine. Such agents may represent potential antipsychotic drugs with improved central/peripheral distribution, and possibly enhanced safety.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Alvir JMJ, Jeffrey PH, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA . (1993): Clozapine-induced agranulocytosis: Incidence and risk factors in the US. N Engl J Med 329: 162–167
Avellini L, Terracina L, Gaiti A . (1994): Linoleic acid passage through the blood-brain barrier and a possible effect of age. Neurochem Res 19: 129–133
Baldessarini RJ, Frankenburg FR . (1991): Clozapine—a novel antipsychotic agent. New Engl J Med 24: 746–754
Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM . (1993): Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 9: 117–124
Baldessarini RJ, Jamison KR . (1999): Effects of medical interventions on suicidal behavior: Summary and conclusions. J Clin Psychiatry 60(Suppl 2):117–122
Bazan NG . (1990): Supply of n-3 polyunsaturated fatty acids and their significance in the central nervous system. In Wurtman RJ, Wurtman JJ (eds), Nutrition and the Brain, Vol 8. New York, Raven Press, pp 1–24
Bazan NG, Birkle D, Reddy TS . (1985): Biochemical and nutritional aspects of the metabolism of polyunsaturated fatty acids and phospholipids in experimental models of retinal degenerations. In LaVail MM, Anderson M, Hollyfield J (eds), Retinal Degeneration: Experimental and Clinical Studies. New York, AR Liss, pp 159–187
Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P . (1998): Risperidone vs clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind trial. Am J Psychiatry 155: 499–504
Campbell A, Baldessarini RJ, Cremens MC . (1988): Dose-catalepsy response to haloperidol in rat: Effects of gender and strain. Neuropharmacology 11: 1197–1199
Campbell A, Baldessarini RJ, Cremens C, Teicher MH, Marsh ER . (1989): Bromocriptine antagonizes behavioral effects of cocaine in the rat. Neuropsychopharmacology 2: 209–224
Campbell A, Baldessarini RJ, Gao Y, Ram VJ, Neumeyer JL . (1990): R(−) and S(+) stereoisomers of 11-hydroxy- and 11-methoxy-N-n-propylnoraporphine: Central dopaminergic behavioral activity in the rat. Neuropharmacology 29: 527–536
Campbell A, Baldessarini RJ, Neumeyer JL . (1993): Altered spontaneous behavior and sensitivity to apomorphine in rats following pretreatment with S(+)-aporphines or fluphenazine. Psychopharmacology 111: 351–358
Campbell A, Villavicencio AT, Yeghiayan SK, Balikian R, Baldessarini RJ . (1997): Mapping of locomotor behavioral arousal induced by microinjections of dopamine within nucleus accumbens septi of the rat forebrain. Brain Res 771: 55–62
Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR, Flood JG . (1994): Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with clozapine and fluoxetine or valproate. Am J Psychiatry 151: 123–125
Dehouck B, Fenart L, Dehouck M-P, Pierce A, Torpier G . (1997): A new function for the LDL receptors: Transcytosis of LDL across the blood-brain barrier. J Cell Biol 138: 877–889
Gerlach J . (1991): New antipsychotics: Classification, efficacy and adverse effects. Schizophrenia Bull 17: 289–309
Hägg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R . (1998): Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 59: 294–299
Innis SM . (1991): Essential fatty acids in growth and development. Prog Lipid Res 30: 39–103
Jacob JN, Shashoua VE, Campbell A, Baldessarini RJ . (1985): Synthesis, brain uptake and pharmacological properties of lipid esters of γ-aminobutyric acid. J Med Chem 28: 106–110
Jann MW, Grimsley SR, Gray EC, Chang W . (1993): Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 24: 161–176
Kane JM, Honigfeld G, Singer J, Meltzer HY, Clozaril Collaborative Study Group . (1988): Clozapine for the treatment resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–796
Kula NS, Baldessarini RJ, Kebabian JW, Bakthavachalam V, Xu L . (1997): RBI-257, a highly potent dopamine D4 receptor-selective ligand. Eur J Pharmacol 331: 333–336
Kula NS, Tarazi FI, Baldessarini RJ, Xu L, Bakthavachalam V, Pounds S, True CD . (1998): Neuropharmacological assessment of potential dopamine D4 receptor-selective ratioligands. Eur J Pharmacol 367: 139–142
Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM . (1994): Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome. Am J Psychiatry 151: 1744–1752
Martin RE, Bazan NG . (1992): Changing fatty acid content of growth cone lipids prior to synaptogenesis. J Neurochem 59: 318–325
Martin RE, Rodriguez de Turco EB, Bazan NG . (1994): Developmental maturation of hepatic n-3 polyunsaturated fatty acid metabolism: Supply of docosahexaenoic acid to retina and brain. J Nutr Biochem 5: 151–160
Meltzer HY . (1998): Suicide in schizophrenia: Risk factors and clozapine treatment. J Clin Psychiatry 59(Suppl 3):15–20
Scott BL, Bazan NG . (1989): Membrane docosahexaenoate is supplied to the developing brain and liver by the liver. Proc Natl Acad Sci U S A 86: 2903–2907
Shashoua VE, Hesse GW . (1996): N-docosahexaenoyl-3-hydroxytyramine: A dopaminergic compound that penetrates the blood-brain barrier and suppresses appetite. Life Sci 58: 1347–1357
Söderberg M, Edlund C, Kristensson K, Dallner G . (1991): Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 26: 421–425
Spector R . (1988): Fatty acid transport through the blood-brain barrier. J Neurochem 50: 639–643
Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB . (1999): Omega-3 fatty acids in bipolar disorder. Arch Gen Psychiatry 56: 407–412
Volpicelli S, Centorrino F, Puopolo P, Kando J, Frankenburg FR, Baldessarini RJ, Flood JG . (1993): Determination of clozapine, norclozapine and clozapine-N-oxide in serum by liquid chromatography. Clin Chem 39: 1656–1659
Wahlbeck K, Cheine M, Essali A, Adams C . (1999): Evidence of clozapine's effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials. Am J Psychiatry 156: 990–999
Welch J, Manschreck T, Redmond D . (1994): Clozapine-induced seizures and EEG changes. J Neuropsychiatry Clin Neurosci 6: 250–256
Acknowledgements
Supported, in part, by NIMH grants MH-34006, MH-47370, the Bruce J. Anderson Foundation, the McLean Hospital Private Donors’ Neuropharmacology Research Fund, and a research award from Protarga, Inc.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baldessarini, R., Campbell, A., Webb, N. et al. Fatty Acid Derivatives of Clozapine: Prolonged Antidopaminergic Activity of Docosahexaenoylclozapine in the Rat. Neuropsychopharmacol 24, 55–65 (2001). https://doi.org/10.1016/S0893-133X(00)00173-1
Received:
Revised:
Accepted:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(00)00173-1
Keywords
This article is cited by
-
The dopamine D2 receptor dimer and its interaction with homobivalent antagonists: homology modeling, docking and molecular dynamics
Journal of Molecular Modeling (2016)
